Statins are a widely available, cheap, safe, and extremely effective means to reduce the cardiovascular disease (CVD) risk, and it is therefore a tragedy that these life-saving medicines are under-used. Non-adherence to statin therapy reaches up to 60% after 2 years, and cessation is associated with a significant increase in the risk of CVD events. Much of this […]

Abstract Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin-associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3–5%). Many […]

Abstract The risk of atherosclerotic cardiovascular disease (ASCVD) is strongly related to lifetime exposure to low-density lipoprotein (LDL)-cholesterol in longitudinal studies. Lipid-lowering therapy (using statins, ezetimibe and PCSK9 inhibitors) substantially ameliorates the risk and is associated with long-term reduction in cardiovascular (CV) events. The robust evidence supporting these therapies supports their continued (and expanding) role in risk reduction. In addition […]

Abstract Aims Statin intolerance (SI) represents a significant public health problem for which precise estimates of prevalence are needed. Statin intolerance remains an important clinical challenge, and it is associated with an increased risk of cardiovascular events. This meta-analysis estimates the overall prevalence of SI, the prevalence according to different diagnostic criteria and in different […]

https://ilep.eu/wp-content/movies/20221008082604_live7603_2022-10-08-07.47.08.515-UTC.mp4

The 1st ILEP Symposium has come to an end. Finally, we are ready to share the official statistics of this event. Please see the attached graph and map!   We would also like to once again thank our Partners – Sanofi, Viatris and Amgen. Without them this Symposium would not be possible. Thank you so […]

We are pleased to invite you to participate in a free webinar organized by the European Atherosclerosis Society (EAS) together with The Polish Lipid Association, during which we will talk about lipid disorders and rare diseases. We will discuss issues related to the diagnosis, management, treatment and diagnosis of disorders such as familial hypercholesterolemia, familial […]

Inflammation plays a central role in the pathogenesis and clinical manifestations of atherosclerosis. Randomized controlled trials have investigated the potential benefit of colchicine in reducing cardiovascular (CV) events in patients with coronary artery disease (CAD) but produced conflicting results. The aim of this meta-analysis was to evaluate the efficacy and safety of colchicine in patients […]

Familial hypercholesterolaemia (FH) is a genetic and complex multifactorial lipid disorder, which increases the risk of premature atherosclerosis and coronary artery disease. FH is still underdiagnosed and undertreated globally and clinical strategies for the treatment and management of pediatric patients with this disorder are still far from being optimal. The objective of this position paper […]

Fig. 1. Direct potential causes of myocarditis. Myocarditis is an inflammatory disease of the myocardium that mostly affects young adults. The disease is commonly caused by viral infection, medications, autoimmune disorders, and inflammatory conditions. Nearly 50% of the cases of myocarditis are due to post-viral immune response in a setting of an identifiable or non-identifiable […]